Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlo Ferrari

Showing results (191-200 of 234) with videos related to

Pageof 24
Sort By:
Gastroenterology|April 19, 2006
Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patientsGloria Taliani, Giulia Gemignani, Carlo Ferrari, et al.
Haematologica|January 7, 2017
<i>IL21R</i> expressing CD14<sup>+</sup>CD16<sup>+</sup> monocytes expand in multiple myeloma patients leading to increased osteoclastsMarina Bolzoni, Domenica Ronchetti, Paola Storti, et al.
Science Translational Medicine|September 29, 2017
RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAgChristine I Wooddell, Man-Fung Yuen, Henry Lik-Yuen Chan, et al.
Journal of Hepatology|August 6, 2005
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis CStefan Zeuzem, Jean-Michel Pawlotsky, Esther Lukasiewicz, et al.
Journal of Hepatology|November 7, 2017
Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis BHarry L A Janssen, Maurizia R Brunetto, Yoon Jun Kim, et al.
Health Science Reports|April 3, 2019
Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II)Tarik Asselah, Negar Niki Alami, Christophe Moreno, et al.
Gastroenterology|October 9, 2007
HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project)Massimo Pilli, Alessandro Zerbini, Amalia Penna, et al.
Hepatology (Baltimore, Md.)|October 27, 2019
RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B InfectionMan-Fung Yuen, Ingolf Schiefke, Jung-Hwan Yoon, et al.
Cancers|July 29, 2023
DICER1 Syndrome: A Multicenter Surgical Experience and Systematic ReviewClaudio Spinelli, Marco Ghionzoli, Linda Idrissi Sahli, et al.
Nature Communications|February 1, 2020
Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infectionValeria Barili, Paola Fisicaro, Barbara Montanini, et al.
Pageof 24

Showing results (191-200 of 234) with videos related to

Sort By:
Pageof 24
Gastroenterology|April 19, 2006
Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patientsGloria Taliani, Giulia Gemignani, Carlo Ferrari, et al.
Haematologica|January 7, 2017
<i>IL21R</i> expressing CD14<sup>+</sup>CD16<sup>+</sup> monocytes expand in multiple myeloma patients leading to increased osteoclastsMarina Bolzoni, Domenica Ronchetti, Paola Storti, et al.
Science Translational Medicine|September 29, 2017
RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAgChristine I Wooddell, Man-Fung Yuen, Henry Lik-Yuen Chan, et al.
Journal of Hepatology|August 6, 2005
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis CStefan Zeuzem, Jean-Michel Pawlotsky, Esther Lukasiewicz, et al.
Journal of Hepatology|November 7, 2017
Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis BHarry L A Janssen, Maurizia R Brunetto, Yoon Jun Kim, et al.
Health Science Reports|April 3, 2019
Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II)Tarik Asselah, Negar Niki Alami, Christophe Moreno, et al.
Gastroenterology|October 9, 2007
HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project)Massimo Pilli, Alessandro Zerbini, Amalia Penna, et al.
Hepatology (Baltimore, Md.)|October 27, 2019
RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B InfectionMan-Fung Yuen, Ingolf Schiefke, Jung-Hwan Yoon, et al.
Cancers|July 29, 2023
DICER1 Syndrome: A Multicenter Surgical Experience and Systematic ReviewClaudio Spinelli, Marco Ghionzoli, Linda Idrissi Sahli, et al.
Nature Communications|February 1, 2020
Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infectionValeria Barili, Paola Fisicaro, Barbara Montanini, et al.
Pageof 24